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ABSTRACT
 
Objectives:
 
This study analyzes the longitudinal metric
attributes of three Parkinson’s disease (PD) disability scales,
taking Hoehn and Yahr (HY) staging as the reference meas-
ure of PD progression.
 
Methods:
 
A sample of 87 PD patients was assessed during
regular medical visits, using the HY, the Uniﬁed Parkinson’s
Disease Rating Scale—Activities of Daily Living Section
(UPDRS-ADL), the Schwab and England Scale (SES), and the
Intermediate Scale for Assessment of PD (ISAPD), across a
follow-up period of 2.6 
 
±
 
 1.0 years.
 
Results:
 
The following cross-sectional attributes were ana-
lyzed, at baseline and again on conclusion of the study: ﬂoor
and ceiling effects, convergent validity, reliability, and stand-
ard error of measurement, all of which were found to be
adequate. Longitudinal reproducibility values (intraclass cor-
relation coefﬁcient) were 0.81 (ISAPD) to 0.84 (UPDRS-
ADL). Insofar as longitudinal validity was concerned, the
change scores of the three disability scales correlated signif-
icantly with the HY change score, |
 
r
 
| 
 
=
 
 0.33 to 0.45,
 
P
 
 
 
<
 
 0.003. Slightly lower values were found when taking the
annual rate of change, |
 
r
 
| 
 
=
 
 0.20 to 0.36. The three scales
were acceptable, even though there were small differences
among them. The “minimal clinically important difference”
proposed for these scales is: SES, 
 
−
 
6; UPDRS-ADL, 
 
+
 
2;
ISAPD, 
 
+
 
1.5 points.
 
Conclusions:
 
The three scales proved adequate for longitu-
dinal assessment of PD disability. UPDRS-ADL was more
precise and ISAPD more consistent. Magnitude of change
and correlation with change in HY were slightly higher with
the ISAPD. Effect size and standardized response mean for
the minimal change in HY were higher for the UPDRS-ADL.
 
Keywords:
 
 Hoehn and Yahr Scale, ISAPD, Longitudinal met-
ric properties, Parkinson’s disease, Schwab and England
Scale, UPDRS.
 
Introduction
 
Parkinson’s disease (PD) is a progressive disorder.
Over time, motor (tremor, hypokinesia, rigidity, gait,
and balance disorder) and nonmotor symptoms
(depression, cognitive impairment, sleep disturbances,
constipation, etc.) increase in severity or are added to
the previous manifestations as new aspects of the dis-
ease. Growing disability is the consequence of this
evolutionary sequence. In advanced stages of disease,
even the basic activities of daily living (ADL) are
severely limited or impossible to perform without
help.
In clinical practice and research, assessment of PD
patients is usually carried out using rating scales such
as: the Uniﬁed Parkinson’s Disease Rating Scale—Ver-
sion 3.0 (UPDRS) [1,2]; the most frequently used
evaluative method in PD, the Intermediate Scale for
Assessment of PD (ISAPD) [3,4]; the Short Parkinson’s
Evaluation Scale [5]; or the Scales for Outcomes in PD
[6].
Despite there being abundant information on cer-
tain metric properties of these scales, very few studies
have addressed longitudinal metric attributes, which
are important for a proper interpretation of attributes
related to change. There is a wide variety of method-
ological proposals to explore responsiveness (ability to
detect change), although there is no consensus about
their best use and respective advantages when com-
pared with one another [7–16]. Even the meaning of
this term may be construed in different ways [15].
These aspects have not been systematically explored in
the realm of PD rating scales.
This study sought to test the cross-sectional and
longitudinal psychometric properties of three PD rat-
ing scales, namely: the Schwab and England Scale
(SES), the Uniﬁed Parkinson’s Disease Rating Scale—
Activities of Daily Living Section (UPDRS-ADL), and
the ISAPD. Hoehn and Yahr (HY) staging was used
both as a reference measure of PD severity and as a
means to derive a minimal clinically important differ-
ence (MCID) for the above scales.
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There are no studies that analyze longitudinally the
metric attributes of these scales. Identiﬁcation of the
scales with better psychometric properties will inﬂu-
ence the quality of patients’ assessment. In PD, on the
other hand, it is important to determine the changes in
the scores produced over the time because it reﬂects the
evolutionary course of the disease. These changes,
along with MCID, are important to judge the genuine
effects of treatment, as well as to calculate sample sizes
in future research studies.
 
Methods
 
Design
 
Observational, long-term follow-up.
 
Setting
 
A specialized outpatient facility attached to a general
hospital.
 
Patients
 
Eighty-seven patients were included in the study. All
had clinical diagnosis of PD based on the following
modiﬁed UK Parkinson’s Disease Society Brain Bank
operative criteria [17]: 1) insidious onset, at age of
35 years or older; 2) progressive disorder; 3) bradyki-
nesia plus  at  least  one  of  the  following:  rigidity,
rest tremor, and gait disorder/postural instability; 4)
no “red ﬂags” indicative of “parkinsonism-plus syn-
drome” or secondary parkinsonism by history, exam-
ination or ancillary proofs; 5) maintained and obvious
beneﬁt induced by dopaminergic treatment. Most
patients (89.5%) were in treatment with levodopa
(10.6% in monotherapy); 68.8% received dopamine
agonists (3.5% in monotherapy), 18.5% selegiline
(2.1% in monotherapy), and 14.2% amantadine.
Patients were not involved in any clinical trial.
 
Assessment
 
Assessment was in all cases made by the same neurol-
ogist during regular visits, every 3 to 6 months,
depending on the individualized care regimen pre-
scribed for each patient. The measures applied were:
HY, SES, UPDRS-3.0 [1], and ISAPD [4].
The HY was developed in the prelevodopa era [18]
as an indicator of the evolutionary stage of the disease.
It is a neurologist-based rating, widely used in clinical
practice and research. The original scale contains six
levels, ranging from 0 (no sign of disease) to 5 (wheel-
chair-bound or bedridden unless aided). A modiﬁed
version including eight stages (0, 1, 1.5, 2, 2.5, 3, 4,
and 5) was added to the UPDRS and is commonly
used, although it has never been formally validated.
HY staging determines patient’s overall condition, tak-
ing impairments and disability into account simultane-
ously. The HY scale is universally used as a global
indicator of severity, despite ambiguities and limita-
tions mainly derived from heterogeneity in content and
irregular metric structure (for instance, impairments
and disability are simultaneously assessed; some
stages, but not others, are related to laterality), and
nonlinearity between disease progression and HY
stages. A critical review of the HY has recently been
conducted by an ad hoc Task Force of the Movement
Disorder Society [19]. In their conclusions, the Task
Force states “In research settings, the scale is useful
primarily . . . as a validation standard for other rating
instruments.” The HY scale used in this study was the
modiﬁed eight-stage version, which allows for minimal
0.5 changes.
The SES is a rating scale that determines functional
ability and need for help to perform ADL as perceived
by the patient [20]. SES scoring is awarded by inter-
view, and ranges, in 11 steps, from 100% (Completely
independent; Able to do all chores without slowness,
difﬁculty, or impairment; Essentially normal; Unaware
of any difﬁculty) to 0% (Vegetative functions such as
swallowing; Bladder and bowel functions are not func-
tioning; Bedridden). Despite its apparent simplicity,
the application of the SES may pose important prob-
lems because its administration is not standardized in
terms of raters (physicians, fellows, nurses, caregivers),
checking (looking at or not the scale form), and phase
in which it is applied (“on,” “off,” both) [21]. Never-
theless, it is widely used and also is a component of the
UPDRS [1].
The UPDRS is the reference scale for clinical prac-
tice and research, and is also the measure accepted by
European and US regulatory agencies [2]. Moreover,
it  is  the  most  widely  studied  PD  rating  scale  from
a clinimetric point of view [22–25]. The metric
strengths and weaknesses of this scale have been
reviewed by an ad hoc Task Force of the Movement
Disorder Society [2]. The UPDRS is a neurologist-
based measure composed of four sections: 1) Menta-
tion, behavior, and mood (four items); 2) ADL (13
items); 3) Motor examination (14 items); and 4)
Complications of therapy (11 items). Options of scor-
ing for each item range from 0 (normal) to 4 (severe),
except for seven items in section 4 that score 0 (no) or
1 (yes). Usually, data pertaining to sections 1, 2, and
4 are obtained by interview, whereas section 3 is
scored by examination. As alternative forms, a ver-
sion of section 2 may be used for self-assessment
[26,27] and a section 3 version for nurses is available
[28]. As previously mentioned, HY staging and SES
complement the UPDRS [1].
The ISAPD is a rapid scale for use in daily practice
and research [4]. It comprises 13 items, scored from
0 (normal) to 3 (severe) by interview (11 items) and
examination (two items). The ISAPD is mainly geared
to evaluation of functional aspects. In addition, it
includes a four-item subscale for assessment of motor
complications (dyskinesias and ﬂuctuations), which
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was not considered for the present study. The psycho-
metric properties of the ISAPD have been found to be
satisfactory [4,29].
 
Data Analysis
 
Descriptive statistics of demographic and historical
data were expressed as mean, standard deviation
(SD), median, range, or percentage, as appropriate.
For each analysis the used scores were those obtained
at the start of the study (Time 1, T1) and at the end
of the study (Time 2, T2). As a result of the non-
normal distribution of data, the Wilcoxon test was
applied for data comparison. The magnitude of
change observed in the scale scores included percent-
age change and relative change 
 
=
 
 (mean
 
T2
 
 
 
−
 
 mean
 
T1
 
)/
mean
 
T1
 
 [30–32].
The following attributes of the targeted scales were
cross-sectionally tested at baseline and again on con-
clusion of the study: acceptability (ﬂoor and ceiling
effect); internal consistency (Cronbach’s alpha; item–
total correlation corrected for overlap); convergent
validity with the global measure of severity (HY) and
the other scales (Spearman correlation coefﬁcients);
and precision (standard error of measurement,
, where 
 
r
 
xx
 
 
 
=
 
 coefﬁcient of reli-
ability) [9,12,33,34].
For longitudinal validity analysis purposes, the fol-
lowing aspects were tested: mean change in scale
scores per category of difference in the global criterion
of severity (HY) (Kruskal–Wallis test) [15]; correlation
(Spearman rank correlation coefﬁcient) between the
change in scale scores and the change in the global
measure of severity [15]; and correlation between the
annual rate of change (ARC 
 
=
 
 [score
 
T2
 
 
 
−
 
 score
 
T1
 
]/
time
 
T2–T1
 
) in the criterion of severity and that of the
scales [35]. The intraclass correlation coefﬁcient (ICC;
model 2, individual) was used to determine the scales
longitudinal reproducibility [15] in the group of
patients who remained stable according the HY scale.
In addition, relative efﬁciency (RES), effect size
(ES), and standardized response mean (SRM) were
used as measures of responsiveness. RES was calcu-
lated as (
 
z
 
-scores
 
1
 
/
 
z
 
-scores
 
2
 
)
 
2
 
, taking the 
 
z
 
-scores from
the Wilcoxon rank test and using the HY as the refer-
ence measure [15,36,37]; ES 
 
=
 
 (mean
 
T2
 
 
 
−
 
 mean
 
T1
 
)/SD
 
T1
 
[14–16,38,39]; and SRM 
 
=
 
 (mean
 
T2
 
 
 
−
 
 mean
 
T1
 
)/SD
 
difference
 
[14–16,34,40].
The MCID was explored by comparing the change
in scores in the three scales (SES, UPDRS-ADL, and
ISAPD) vis-à-vis the minimal change detected in HY
staging. Two different groups of patients were deﬁned
for this purpose: patients who registered no change
(stable group) and patients who registered an HY 0.5-
stage increase. Difference in scores, percentage change,
ES, and SRM were used to this end. Data analysis was
performed using the STATA computer software pack-
age (version 8.2) [41].
SEM =  SD 1  rxx¥ -
 
Results
 
Eighty-seven patients, 56.3% being men, were
included in the study. Mean 
 
±
 
 SD age of patients was
67.6 
 
±
 
 9.8 years (range: 41–90). At baseline, duration
of the disease was 6.6 
 
±
 
 4.8 (range: 0.5–25) years. The
follow-up period was 2.6 
 
±
 
 1.0 (0.5–4.1) years. A total
of 466 complete evaluations were recorded in this sam-
ple with a median of ﬁve (range, 2–10) assessments per
patient and two assessments per patient-year.
Distribution of patients by HY stage at T1 and T2
is shown in Table 1. According to this measure, 27
patients remained stable, and 22 underwent a 0.5, 21
a 1, and 9 a 1.5 or more increase in HY stage. Eight
patients (9%) who showed an apparent improvement
of 0.5 (seven patients) or one HY stage (one patient),
were discarded from the longitudinal analysis.
Descriptive statistics of the total scores at initial
and follow-up measurements are shown in the Table 2.
The  difference  between  both  time  points  in  the
study proved statistically signiﬁcant (Wilcoxon test,
 
P
 
 
 
≤
 
 0.001). The largest magnitude of change for dif-
ference in percentage and relative change was regis-
tered by the ISAPD and the smallest by the SES
(Table 2).
The basic metric characteristics of the SES, UPDRS-
ADL, and ISAPD, at both points in time, are shown
in Table 3. One UPDRS-ADL item (16. Tremor) dis-
played lower item–total correlation (
 
r
 
 
 
=
 
 0.12–0.13)
than the stipulated criterion value (
 
r
 
 
 
=
 
 0.30) [39], but
the scale is nevertheless considered satisfactory as a
whole [33,34,42,43]. Insofar as longitudinal reproduc-
ibility was concerned, the ICC ranged from 0.84 for
the UPDRS to 0.81 for the ISAPD (Table 3). With
respect to precision, SEM based on the longitudinal
reliability coefﬁcient (ICC), ranged from 2.68 for the
UPDRS-ADL to 5.85 for the SES.
The results of the longitudinal analysis are shown in
Table 4. There was a signiﬁcant trend for the differ-
ence in scale scores to increase as the change in the
reference measure of severity increased. Correlation
between  change  in  the  severity  measure  and  change
in scale scores was moderate (
 
r
 
abs
 
 
 
=
 
 0.33–0.45; all,
 
P
 
 
 
<
 
 0.01). Nevertheless, the intercorrelation between
 
Table 1
 
Distribution of patients according to Hoehn and Yahr
staging
 
T1
T2 
1 1.5 2 2.5 3 4 5 Total
1
 
3
 
3 6 2 14
1.5
 
1
 
5 2 8
2 1
 
13
 
12 8 3 37
2.5 4
 
6
 
2 3 15
3 1 2
 
1
 
5 1 10
4
 
3
 
3
Total 3 5 29 24 11 14 1 87
 
The diagonal in bold represents the number of patients who remained stable.
T1, at baseline; T2, at end of study.
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Table 2
 
Patient scores at baseline (Time 1) and at the end of the study (Time 2), and magnitude of change
 
Time 1 Time 2 Wilcoxon P Difference in % Relative change
Hoehn and Yahr 0.0000
Median 2 2.5
P25–P75 1.5–2.5 2–3
Range 1–4 1–5
Schwab and England 0.0000
 
−
 
0.07
Mean 79.6 73.7
 
−
 
7.3
SD 14.2 17.4 17.9
Median 80 80 0
P25–P75 70–90 60–90
 
−
 
14.3–0
Range 30–100 20–100
 
−
 
66.6–75
UPDRS-ADL 0.001 0.16
Mean 11.6 13.5 40.4
SD 6.7 7.7 97.8
Median 11 12 8.3
P25–P75 6–16 8–18
 
−
 
8.33–62.5
Range 1–30 1–32
 
−
 
85.7–450
ISAPD 0.0006 0.18
Mean 11.5 13.6 53.6
SD 7.1 7.9 149.6
Median 11 12 11.1
P25–P75 6–16 8–19
 
−
 
11.1–44.4
Range 0–34 0–34
 
−
 
87.5–800
 
P25–P75: percentile 25 and 75 (interquartile rank); Range: minimum and maximum. N 
 
=
 
 87.
ISAPD, Intermediate Scale for Assessment of Parkinson’s Disease; UPDRS-ADL, Uniﬁed Parkinson’s Disease Rating Scale—Activities of Daily Living Section.
 
Table 3
 
Cross-sectional attributes of the scales at baseline
(Time 1) and at the end of the study (Time 2)
 
Time 1 Time 2
Criterion
value
[Reference]
Schwab and England Scale
Floor effect (%) 1.15 1.15
 
<
 
10% [42]
Ceiling effect (%) 9.20 2.3
 
<
 
10% [42]
Convergent validity*
 
>
 
0.60 [43]
Hoehn and Yahr staging
 
−
 
0.70
 
−
 
0.81
UPDRS-ADL
 
−
 
0.85
 
−
 
0.85
ISAPD
 
−
 
0.89
 
−
 
0.88
Longitudinal reliability (ICC) 0.83
 
>
 
0.70 [33]
Standard error of
measurement
5.85 —
UPDRS-ADL
Floor effect (%) 2.30 2.30
 
<
 
10% [42]
Ceiling effect (%) 1.15 2.30
 
<
 
10% [42]
Cronbach’s alpha 0.85 0.86
 
>
 
0.70 [33]
Item–total correlation 0.12–0.74 0.13–0.77
 
>
 
0.30 [39]
Convergent validity*
 
>
 
0.60 [43]
Hoehn and Yahr staging 0.70 0.78
ISAPD 0.91 0.92
Longitudinal reliability (ICC) 0.84
 
>
 
0.70 [33]
Standard error of
measurement
2.68 —
ISAPD
Floor effect (%) 4.6 2.3
 
<
 
10% [42]
Ceiling effect (%) 1.15 2.3
 
<
 
10% [42]
Cronbach’s alpha 0.94 0.94
 
>
 
0.70 [33]
Item–total correlation 0.45–0.84 0.42–0.84
 
>
 
0.30 [39]
Convergent validity*
 
>
 
0.60 [43]
Hoehn and Yahr staging 0.70 0.83
Longitudinal reliability (ICC) 0.81
 
>
 
0.70 [33]
Standard error of 
measurement
3.10 —
 
*Spearman 
 
r
 
 (P < 0.0001).
ICC, Intraclass correlation coefﬁcient; ISAPD, Intermediate Scale for Assessment of
Parkinson’s Disease; UPDRS-ADL, Uniﬁed Parkinson’s Disease Rating Scale—Activ-
ities of Daily Living Section. N = 87.
Table 4 Longitudinal analysis of metric attributes
Schwab and 
England change
(mean ± SD)
UPDRS-ADL 
change
(mean ± SD)
ISAPD 
change 
(mean ± SD)
Longitudinal validity
Hoehn and Yahr change (N)
0 (27) −3.3 ± 8.3 0.5 ± 4.3 −0.1 ± 4.8
0.5 (22) −4.1 ± 9.1 2.1 ± 4.87 1.4 ± 4.3
1 (21) −9.5 ± 9.7 2.8 ± 5.4 4.7 ± 4.8
1.5 (5) −12.0 ± 16.4 6.6 ± 4.7 7.2 ± 5.7
2 (4) −27.5 ± 9.6 8.5 ± 3.1 6.7 ± 2.2
Kruskal–Wallis test P = 0.003 P = 0.02 P = 0.002
Correlation of
change in HY
with change in
scale
−0.38;
 P = 0.0006
0.33;
P = 0.003
0.45;
 P < 0.0001
Annual rate of
change
−3.3 ± 5.3 0.8 ± 2.3 0.8 ± 2.3
(95% conﬁdence
interval)
(−4.5 to −2.11) (0.3–1.3) (0.3–1.3)
Correlation
between annual
rates of change
in HY and scale
−0.35
P = 0.001
0.20
NS
0.36
P = 0.001
Responsiveness −0.49 0.35 0.33
Effect size* −0.49 0.35 0.33
Standardized
response mean†
−0.64 0.46 0.46
*References [14–16,38,39].
†References [14–16,34,40].
ISAPD, Intermediate Scale for Assessment of Parkinson’s Disease; NS, nonsigniﬁcant;
UPDRS-ADL, Uniﬁed Parkinson’s Disease Rating Scale—Activities of Daily Living
Section.
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changes captured by the three scales was highly signif-
icant (r = −0.60 [SES with the other two] and 0.87
[UPDRS-ADL with ISAPD]; all, P < 0.0001).
The ARC for HY was 0.21 (median; 95% con-
ﬁdence interval [CI]: 0.13–0.28; range: 0–1.4).
Although the correlation between the annual rates of
change of the HY and UPDRS-ADL was nonsigniﬁ-
cant, it proved moderate for the other two scales
(rabs = 0.35–0.36, P = 0.001) (Table 4). Nevertheless,
a signiﬁcant correlation was found between the
annual  rates  of  change  of  the  respective  scales  (r =
−0.51 [SES with the other two] and 0.83 [UPDRS-ADL
with ISAPD]; all, P < 0.0001).
In the calculation of the RES values, the following
z-scores were obtained using the HY as a comparative
measure:  SE,  T1 = −8.11,  T2 = 8.11;  ISAPD,  T1 =
−7.92, T2 = −7.97; UPDRS, T1 = −8.07, T2 = −8.05.
The three scales attained RES values of 1.00, indicat-
ing that the scales had a similar efﬁciency to that of the
reference measure [37,44]. ES and SRM values proved
greater for the SES (≥0.50, moderate), and equivalent
for the UPDRS-ADL and ISAPD (<0.50, small) (14,
16) (Table 4).
Taking an increase of 0.5 in HY stage as the mini-
mal change determined by the global measure of sever-
ity, and bearing in mind the 95% CI upper limit of
difference in the scores of the stable group (change in
HY = 0), an MCID for each of the target scales was
about: −6 points for the SES; +2 points for the UPDRS-
ADL; and +1.5 for the ISAPD (Table 5). Percentage
change, ES, and SRM for these groups of patients are
also shown in Table 5. Lower values for both ES and
SRM were obtained by the ISAPD. Figure 1 shows the
distribution of scores for each scale among the 0 and
0.5 HY change groups.
Discussion and Conclusions
Although a considerable amount of information is
available on the metric properties of PD rating scales
[29], there are no studies that report on the compari-
son of the cross-sectional and longitudinal character-
istics of their psychometric attributes. After identifying
this knowledge gap, we sought to use the methodology
proposed for testing these properties on a set of scales
that were simultaneously applied during the follow-up
of a series of PD patients attended at a specialized out-
patient facility of a general hospital. The natural ten-
dency of PD to progress over time, regardless of the
best treatment available, was considered the main
factor capable of generating change in this series of
patients.
HY staging was used as the reference measure of
severity because it “has remained the most commonly
and most widely used scale to describe severity of PD
worldwide. It is the standard staging system used to
describe patient populations enrolled in clinical trials”
[19, p. 1022]. According to this scale, most patients in
this study (60%) worsened, and almost one-third
Table 5 Parameters of change in relation to the reference
measure (Hoehn and Yahr staging)
Change in 
Hoehn and Yahr
Difference in score
mean ± SD
(95% CI)
% change 
mean ± SD
(95% CI) ES SRM
Schwab and England Scale
0 −3.3 ± 8.3
(−6.6–0.04)
−3.9 ± 10.1
(−7.9–0.1)
−0.22 −0.40
+0.5 −4.1 ± 9.1
(−8.1 to −0.1)
−4.5 ± 12.6
(−10.1–1.1)
−0.39 −0.45
UPDRS—Activities of Daily Living
0 0.5 ± 4.3
(−1.1–2.2)
21.2 ± 64.7
(−4.4–46.8)
0.07 0.13
+0.5 2.1 ± 4.8
(0.0–4.3)
40.4 ± 108.0
(−7.5–88.2)
0.53 0.44
Intermediate Scale for Assessment of Parkinson’s Disease
0 −0.1 ± 4.8
(−2.0–1.7)
29.0 ± 127.3
(−21.3–79.4)
−0.02 −0.03
+0.5 1.4 ± 4.3
(−0.5–3.3)
38.6 ± 109.8
(−10.0–87.4)
0.32 0.33
N = 27 for stable patients (change in Hoehn and Yahr stage = 0) and n = 27 for
patients who changed +0.5 Hoehn and Yahr stage.
CI, conﬁdence interval; ES, effect size; SRM, standardized response mean; UPDRS,
Uniﬁed Parkinson’s Disease Rating Scale.
Figure 1 Mean difference in Schwab and Eng-
land Scale (SE), Uniﬁed Parkinson’s Disease Rat-
ing Scale—Activities of Daily Living (UPDRS-
ADL) and Intermediate Scale for Assessment of
Parkinson’s Disease (ISAPD) scores by change
in Hoehn and Yahr (HY).
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(31%) remained in the same stage across the study
period (Tables 1 and 4). The scores of the targeted dis-
ability scales reﬂected this overall trend to a statisti-
cally signiﬁcant degree and with diverse magnitudes of
change (maximum for the ISAPD, minimum for the
SES) (Table 2).
On the whole, the metric properties tested in these
scales proved satisfactory vis-à-vis demanding criteria
[33,39,42,43], at both T1 and T2 and longitudinally.
Longitudinal reproducibility was assessed by means
of the ICC, using baseline and follow-up scores of sta-
ble patients. These coefﬁcients attained equivalent
values for the three scales and were higher than the
threshold of 0.70 accepted as the criterion value in
the setting of the present study [39]. This attribute is
linked to the internal consistency of the scale at each
time point [15] and inﬂuences the SEM, which
resulted smaller for the UPDRS-ADL and bigger for
the SES. Accordingly, the results conﬁrm that these
measures possess adequate cross-sectional and longi-
tudinal metric attributes, namely, acceptability, inter-
nal consistency, reliability, convergent validity, and
precision.
Some authorities state that ability to measure
change over time should be regarded as “longitudinal
(construct) validity,” whereas “responsiveness” is the
ability to measure changes induced by treatment
[15,45,46]. An additional distinction by Husted et al.
[8] differentiates “internal responsiveness” (the ability
to measure change over time) from “external respon-
siveness” (the extent to which changes in a measure
over time are related to corresponding changes in a ref-
erence measure). This relevant distinction is related to
the use of distribution-based and anchor-based meth-
ods, respectively, for assessment of interpretability
[15].
In the present study, the longitudinal validity of the
three scales was tested using HY staging as the refer-
ence measure. The magnitude of the change in scale
scores was broken down by the magnitude of change
in the reference measure, and showed a signiﬁcant
trend for the difference in scores to increase as the
change in the standard increased. In addition, two dif-
ferent correlational approaches were used: the ﬁrst
explored the association between the change in the ref-
erence measure and the change captured by each of the
scales; the second used the corresponding ARC rather
than the raw scores.
The results of this analysis are indicative of a sig-
niﬁcant, although moderate, association between the
standard (HY) and the rating scales. Correlation
proved looser for the UPDRS-ADL and tighter for the
ISAPD (Table 4). Some UPDRS-ADL items (salivation,
swallowing, falling, freezing, and sensory complaints)
are more properly impairments than disabilities [2,29],
something that may explain discrepancies when eval-
uations focus speciﬁcally on disability.
Correlation was closer among the scales than
between the scales and the HY. As previously men-
tioned, the latter instrument is heterogeneous in con-
tent and is not linear in relation to disease progression
[19]. In contrast, the rating scales tested here are more
regular in structure, ultimately allowing for a close
association among them.
The RES is a comparative measure of responsive-
ness (ability of an index to measure clinical change)
[15,36,37,40], used to compare an instrument to a
standard in terms of its efﬁciency to detect change
[37,44]. Subsequently, comparative sample-size calcu-
lations can be derived from this statistic. A score of 1
indicates the same efﬁciency, less than 1 means that the
standard is more efﬁcient, and values higher than 1
indicate that the assessed instrument is more efﬁcient
than the standard. In the present study, the three scales
obtained an RES value of 1. According to this ﬁnding,
which can be considered as falling within the context
of “external responsiveness” evaluation of instruments
[8], scale and reference measure efﬁciency were the
same.
ES is a distribution-based method that furnishes
information on the magnitude of change, in terms of a
measure of variation (the SD) at baseline. It is widely
used in clinical trials because ES values are easy to gen-
erate and offer an immediate comparison with hypoth-
esized outcomes or benchmark values [7,8,14–
16,33,38,47]. SRM is a statistic of the “effect-size”
family, in which the denominator is the SD of change
[8,14–16,34]. Limitations of these methods are varia-
bility (dependence on the population under study),
lack of intuitive meaning of the results, arbitrariness
of the reference values, and potential concealment of
weaknesses and effect at an item level when using total
scores [47–49]. More importantly, when there is no
prespeciﬁed hypothesis about the magnitude of the
change (as an effect of intervention), effect-size meth-
ods are not informative as regards the instrument’s
ability to detect change. Indeed, a discrepancy between
the results of the longitudinal analysis and the ES is
evident in our study. The SES yielded the highest ES
and SRM, even though it was not the most valid, reli-
able, and precise scale. This ﬁnding is in line with
advice against the use of treatment-effect measures to
assess longitudinal validity [15,50].
Bearing this advice in mind, an MCID [51] was cal-
culated for the minimal determinable change in the ref-
erence measure, i.e., an increase of 0.5 in HY staging.
Impairment was considered “the effect,” and disease
progression over time, the causal factor. This minimal
important difference can help understand score
changes, although it can also lead to confounded esti-
mates of the overall effect [50].
This study’s limitations are related to the small sam-
ple size for subgroup analysis, which hampers gener-
alization of the results. Nonetheless, assessment of the
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patients was uniform during the follow-up, a fact con-
tributing consistency to the data. As mentioned above,
the choice of HY as reference measure poses problems
linked to the intrinsic characteristics of this instru-
ment. Nevertheless, the HY scale is universally used as
a standard for PD staging [19]. The assumed linear
change over time (e.g., by using the ARC statistic or
deeming differences in 0.5 HY stage to be homogene-
ous) is probably not true in reality. However, the
course of the disease is very variable and there is no
single all-embracing model of progression [52,53].
Finally, limitations linked to the use of anchor-based
and distribution-based methods [8,14,15] should also
be taken into account in this study.
To sum up, longitudinal analysis shows that the
SES, UPDRS-ADL, and ISAPD are valid measures for
follow-up of PD patients, being almost equivalent in
quality of their metric attributes. The UPDRS-ADL
was more precise and the ISAPD more consistent.
Magnitude of change (in percentage and relative
change) and correlation with the change and ARC in
HY were slightly higher with the ISAPD (Table 4).
MCID ranged from 1.5 for the ISAPD to −6 for the
SES. ES and SRM for the minimal change in HY (+0.5)
were higher for the UPDRS-ADL.
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